Michele Pighi

The PCR Community mourns the passing of Michele Pighi, Interventional Cardiologist, as the result of a tragic accident.

Pierre Deharo and Michele Pighi share with us their views on the EXIT-CALC study presented by Thomas Oomens at TCT 2022.

Thanks to the contribution of a team of interventional cardiologists from around the globe, view the international perspective on Late-breaking Clinical Trials and Science released at TCT 2022 - check out the list here!

The primary objective of the study was to assess whether an IVUS-based stent optimization provided an incremental value in terms of vessel-related adverse event occurrence in patients presenting with low post-PCI FFR (<0.90).

Michele Pighi provides his take on this trial which aimed to compare the safety and efficacy of VIV-TAVI with or without bioprosthetic valve fracture. It was presented by Santiago Garcia during the TCT Congress 2022.

Find out more about how the authors managed a 53-year old male with ischemic cardiomyopathy, EF 25 %, and calcified 3-vessel disease ! 

This study investigated the short-term safety and efficacy of the new valve ACURATE neo2 in comparison to the first neo model in a real-world population.

This report builds up the evidence on the relevance of extra-valvular cardiac damage staging / involvement as a main predictor of adverse events in patients with VHD undergoing intervention, either surgical or percutaneous.

This EuroPCR 2022 session presents innovative types of coronary approches used in different Clinical Case submissions: severe calcific tortuous LAD disease, the calcium challenge or IVUS-guided CTO PCI with minimum contrast...

Consult this session to discover some interventions to facilitate transfemoral TAVI in challenging situations, such as: coarctation and aortic stenosis with very high surgical risk, severe aortic stenosis with large infra-renal abdominal aneurysm, severe circumferential calcified bilateral iliac stenosis with thick protruding nodules, and much more!

TAVI and thrombocytopenia, TAVI, CAD and hepatocarcinoma, or even severe aortic regurgitation and ovarian cancer with infective endocarditis: analyze the case of different cancer patients to be treated for cardiac pathologies in this session from EuroPCR 2022.

Consider an 86-year-old man with acute chest pain and history of HTN, HLP, DM, renal insufficiency, peripheral artery disease, PTA, urocystic cancer, and TIA, and discuss how to treat this very complex patient combining all the problems we face every day in one person.

Watch this session on valve-in-valve to learn how to deal with challenging procedures: FIH experience with first dedicated transcatheter leaflet splitting device, bioprosthesis haemodynamics and coronary flow after TAVI in TAVI, and simultaneous complex transcatheter treatment for degenerated prosthetic valves. 

Techniques to manage simultaneously severe calcified aortic stenosis and severe heavily calcified ostial RCA disease combining TAVI and ROTABLATION.

Michele Pighi provides his take on the National Cardiovascular LAAO Registry that analyzed data from 51,333 patients who underwent LAAO procedures with the WATCHMAN device between 2016-2019, as part of the College's NCDR registries.

Live updates on a selection of major Late Breaking Clinical Trials of interest in interventional cardiology presented at the American College of Cardiology 2022 Scientific Sessions #ACC22.

The objective of this analysis was to evaluate the impact of residual ischemia detected by post-PCI iFR on clinical outcomes and on residual-angina at the 12-month follow-up of the DEFINE PCI study.

This PCR London Valves 2021 session dedicated to mitral transcatheter edge-to-edge repair will enable you to understand this specific therapy by the use of anatomical specimens, imaging, and simulations.

Here is an anthology of unexpected complications encountered during TAVI treatment: cardiac arrest during TAVI, ascending aortic pseudoaneurysm after TAVI, enterococcus faecalis abscess after TAVI, and much more in this PCR London Valves 2021 session.

Although TAVI is an accepted alternative to surgery in patients with severe aortic stenosis who are at high surgical risk, less is known about long-term comparative outcomes among patients with aortic stenosis who are at intermediate surgical risk. P. Redaelli & M. Pighi review the SURTAVI trial...

Thanks to the contribution of a team of interventional cardiologists from around the globe, view the international perspective on Late-breaking Clinical Trials and Science released at TCT 2021 - check out the list here!

Find out more about how the authors managed a 79-year-old male presenting with ACS and lateral ischemia with a calcified and tortuous left circumflex that could not be crossed with balloons... and a 61-year-old male with inferior STEMI presenting with an “undilatable” lesion of the right coronary artery...

Reviewers:

Michele Pighi, Pierre Deharo and Flavio Luciano Ribichini

According to the updated international revascularization guidelines, fractional flow reserve (FFR) and instantaneous wave-free period ratio (iFR) are proposed to dichotomize decision-making for ischemia detection in guiding percutaneous coronary intervention (PCI) of intermediate coronary stenosis.

Find out more about the case of a 72-year-old male, very active, previous smoker with hypertension, who underwent a stress echo for dyspnea on exertion...

Reviewers:

Michele Pighi et Flavio Luciano Ribichini

The aim of this study was to understand the impact of optical coherence tomography (OCT)-detected thin-cap fibroatheroma (TCFA) on clinical outcomes of diabetes mellitus (DM) patients with fractional flow reserve (FFR)-negative lesions.

Find out more about the case of a 70-year-old male with previous heart transplantation at 48 yo due to IHD, claudication of the right leg, and PTA of iliac arteries...

Examination of the study methodology and results according to the PICOT principle, SWOT analysis and real-world applicability of the EBC MAIN trial presented at EuroPCR 2021.

This investigator-initiated randomised, open-label, multicentre trial compares FFR versus angiography guided strategies for treating non-culprit lesions in patients presenting with STEMI and multivessel coronary artery disease. The results of this study were released during ACC.21.

Using patient-level data from the Disrupt CAD I, II, III and IV trials, this pooled analysis assesses the efficacy and safety of intravascular lithotripsy in de novo calcified coronary lesions.